Massachusetts Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $149M | Buy |
327,498
+115,564
| +55% | +$53.9M | 0.05% | 301 |
|
|
2025
Q4 | $96.1M | Sell |
211,934
-291,226
| -58% | -$126M | 0.03% | 386 |
|
|
2025
Q3 | $197M | Sell |
503,160
-781,194
| -61% | -$326M | 0.06% | 286 |
|
|
2025
Q2 | $572M | Sell |
1,284,354
-740,554
| -37% | -$341M | 0.18% | 137 |
|
|
2025
Q1 | $982M | Sell |
2,024,908
-263,590
| -12% | -$123M | 0.33% | 89 |
|
|
2024
Q4 | $922M | Sell |
2,288,498
-617,207
| -21% | -$286M | 0.29% | 92 |
|
|
2024
Q3 | $1.35B | Buy |
2,905,705
+159,693
| +6% | +$76.7M | 0.4% | 70 |
|
|
2024
Q2 | $1.29B | Sell |
2,746,012
-58,176
| -2% | -$25.3M | 0.4% | 76 |
|
|
2024
Q1 | $1.17B | Sell |
2,804,188
-821,614
| -23% | -$347M | 0.35% | 84 |
|
|
2023
Q4 | $1.48B | Sell |
3,625,802
-265,992
| -7% | -$98.3M | 0.48% | 58 |
|
|
2023
Q3 | $1.35B | Sell |
3,891,794
-49,327
| -1% | -$17.3M | 0.47% | 57 |
|
|
2023
Q2 | $1.39B | Sell |
3,941,121
-103,910
| -3% | -$35M | 0.46% | 64 |
|
|
2023
Q1 | $1.27B | Sell |
4,045,031
-66,524
| -2% | -$20M | 0.44% | 67 |
|
|
2022
Q4 | $1.19B | Sell |
4,111,555
-235,176
| -5% | -$71.7M | 0.41% | 68 |
|
|
2022
Q3 | $1.26B | Buy |
4,346,731
+4,619
| +0.1% | +$1.33M | 0.47% | 60 |
|
|
2022
Q2 | $1.22B | Buy |
4,342,112
+826,959
| +24% | +$221M | 0.42% | 67 |
|
|
2022
Q1 | $917M | Buy |
3,515,153
+320,475
| +10% | +$76.1M | 0.27% | 97 |
|
|
2021
Q4 | $702M | Buy |
3,194,678
+45,438
| +1% | +$8.84M | 0.19% | 131 |
|
|
2021
Q3 | $571M | Sell |
3,149,240
-4,547
| -0.1% | -$888K | 0.17% | 143 |
|
|
2021
Q2 | $636M | Buy |
3,153,787
+297,171
| +10% | +$62.2M | 0.19% | 132 |
|
|
2021
Q1 | $614M | Buy |
2,856,616
+222,507
| +8% | +$48.9M | 0.19% | 133 |
|
|
2020
Q4 | $623M | Buy |
2,634,109
+733,952
| +39% | +$168M | 0.2% | 129 |
|
|
2020
Q3 | $517M | Buy |
1,900,157
+91,876
| +5% | +$25.3M | 0.19% | 130 |
|
|
2020
Q2 | $525M | Buy |
1,808,281
+581,495
| +47% | +$158M | 0.21% | 117 |
|
|
2020
Q1 | $292M | Buy |
1,226,786
+103,158
| +9% | +$23.7M | 0.14% | 152 |
|
|
2019
Q4 | $246M | Sell |
1,123,628
-96,312
| -8% | -$19.5M | 0.09% | 188 |
|
|
2019
Q3 | $207M | Sell |
1,219,940
-720,436
| -37% | -$127M | 0.08% | 198 |
|
|
2019
Q2 | $356M | Sell |
1,940,376
-35,218
| -2% | -$6.16M | 0.15% | 152 |
|
|
2019
Q1 | $363M | Buy |
1,975,594
+64,583
| +3% | +$11.9M | 0.15% | 146 |
|
|
2018
Q4 | $317M | Buy |
1,911,011
+71,366
| +4% | +$12.4M | 0.15% | 139 |
|
|
2018
Q3 | $355M | Buy |
1,839,645
+176,093
| +11% | +$31.4M | 0.15% | 148 |
|
|
2018
Q2 | $283M | Buy |
1,663,552
+143,730
| +9% | +$22.3M | 0.12% | 166 |
|
|
2018
Q1 | $248M | Buy |
+1,519,822
| New | +$248M | 0.11% | 179 |
|
|
2016
Q1 | – | Sell |
-483,078
| Closed | -$60.8M | – | 878 |
|
|
2015
Q4 | $60.8M | Sell |
483,078
-82,442
| -15% | -$9.95M | 0.03% | 311 |
|
|
2015
Q3 | $58.9M | Buy |
565,520
+18,469
| +3% | +$2.37M | 0.03% | 308 |
|
|
2015
Q2 | $67.5M | Buy |
547,051
+105,748
| +24% | +$13.3M | 0.03% | 299 |
|
|
2015
Q1 | $52.1M | Sell |
441,303
-250,865
| -36% | -$30.1M | 0.03% | 344 |
|
|
2014
Q4 | $82.2M | Buy |
692,168
+178,012
| +35% | +$20M | 0.04% | 268 |
|
|
2014
Q3 | $57.7M | Buy |
+514,156
| New | +$49M | 0.03% | 321 |
|
|
2014
Q2 | – | Sell |
-78,710
| Closed | -$5.57M | – | 919 |
|
|
2014
Q1 | $5.57M | Sell |
78,710
-1,440
| -2% | -$114K | ﹤0.01% | 617 |
|
|
2013
Q4 | $5.96M | Sell |
80,150
-1,010
| -1% | -$70.3K | ﹤0.01% | 595 |
|
|
2013
Q3 | $6.15M | Sell |
81,160
-1,180
| -1% | -$93.9K | ﹤0.01% | 591 |
|
|
2013
Q2 | $6.59M | Buy |
+82,340
| New | +$6.06M | ﹤0.01% | 563 |
|
Other funds holding VRTX
VCM
VPM
Massachusetts Financial Services's VRTX Position: Q1 2026 in Review
Massachusetts Financial Services increased its Vertex Pharmaceuticals (VRTX) stake by 55% in Q1 2026, buying an estimated $53.9M and bringing the position to 327,498 shares worth $149M. The position accounts for 0.05% of the portfolio, ranked #301.
Massachusetts Financial Services first reported a position in VRTX in Q2 2013 and has held it in 43 quarters since. The position peaked at $1.48B in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Massachusetts Financial Services held 327,498 shares of Vertex Pharmaceuticals worth $149M as of Q1 2026.
- Massachusetts Financial Services bought 115,564 Vertex Pharmaceuticals shares in Q1 2026, an estimated $53.9M.
- Vertex Pharmaceuticals made up 0.05% of Massachusetts Financial Services's portfolio in Q1 2026, its #301 holding.
- Massachusetts Financial Services first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Massachusetts Financial Services's Vertex Pharmaceuticals position peaked at $1.48B in Q4 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Massachusetts Financial Services's 13F filing for Q1 2026, filed 14 May 2026.